Clinical and Experimental RHEUMATOLOGY Supplement: Quantitative Clinical Assessment of Rheumatic Diseases

A Journal-based Continuing Medical Education (CME) Activity jointly sponsored by Vanderbilt University School of Medicine and Health Report Services

How to obtain CME credit

To receive your CME credit, you must

- 1. Read the article in the monograph
- 2. Answer the multiple choice questions below for each article read, by either

going to the Vanderbilt CME web site https://medschool.mc.vanderbilt.edu/cme/assessrheum/user/login.php and following the instructions; you will be able to print a certificate if you answer 67% of the questions correctly or

answering the questions below, responding to the evaluation questions, providing the personal information requested, and faxing this form to 001 (615) 322-4526 or mailing it to Division of CME (Clin Exp Rheumatol), Vanderbilt University School of Medicine, 320 Light Hall, Nashville TN 37232-0260. If you have answered 67% of the questions correctly, you will be mailed a CME certificate within 4 weeks.

CME Evaluation Questions

1.	Did the material presented promote a drug or medical device?NoYes If yes, please explain:
2.	Do you plan to implement changes in your practice based on the material presented?NoYes If yes, please explain:
Pe	ersonal Information
La	st Name First Name MI
Bi	thday (Mo.) (Day) (Yr.) Degree Specialty
Ma	iling address
Cit	y/State/Zip
Bu	siness telephone Fax no
E-1	nail

I.a.

Complexities in quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care – *T. Pincus & T. Sokka*

- **1.** A major problem in quantitative assessment of all rheumatic diseases is:
 - **a.** Asingle gold standard blood test is not available to assess and monitor patient status in any rheumatic disease **b.** Many people with positive laboratory tests do not have a disease
 - c. Most rheumatologists do not perform quantitative formal joint counts in most patients with rheumatoid arthritis
 - **d.** All of the above
- 2. The most significant measure in predicting work disability and premature mortality in patients with rheumatoid arthritis in comprehensive published reports of long-term outcomes is:
 - a. Rheumatoid factor
 - b. Radiographic score
 - c. Patient questionnaire physical function score
 - d. Patient questionnaire pain score
- **3.** Different <u>clinical</u> indices to assess disease activity or organ damage have been developed for each of the following rheumatic diseases except:
 - **a.** Systemic lupus erythematosus
 - b. Ankylosing spondylitis
 - c. Rheumatoid arthritis
 - d. Vasculitis

I.b.

OMERACT: An international initiative to improve outcome measurements in rheumatology – *M. Boers, P. Brooks, L.S. Simon, V. Strand & P. Tugwell*

- 1. The term "OMERACT" stands for:
 - a. Outstanding measures of rheumatoid arthritis clinical therapies
 - b. Omnibus methods for rheumatology clinical trials
 - c. Outcome measures in rheumatoid arthritis clinical trials
 - d. Open meetings to evaluate rheumatoid arthritis care and therapy.
- 2. The first OMERACT meeting was held in:
 - **a.** The Netherlands in 1992
 - **b.** Switzerland in 1985
 - c. The Netherlands in 1982
 - **d.** Canada in 1988
- 3. OMERACT meetings have addressed assessment of which disease:
 - a. Osteoarthritis
 - b. Osteoporosis
 - **c.** Ankylosing spondylitis
 - **d.** All of the above

II.a.

The Health Assessment Questionnaire (HAQ) - B. Bruce & J.F. Fries

- 1. Which is the most accurate statement about the Full HAQ?
 - **a.** The Full HAQ is available in more than 60 languages, whereas the Short HAQ is available only for English-speaking patients
 - **b.** The Full HAQ contains only the HAQ disability index and pain and global visual analog scales
 - **c.** The Full HAQ gathers data on all five dimensions of health outcome, as well as demographics, and lifestyle and health behaviors
 - **d.** The Full HAQ is a scannable version of the HAQ that assesses only physical abilities, health behaviors and pain

- 2. Studies of patient-centered health values have tended to yield data indicating that:
 - a. Patients are concerned only about their functional status, their pain and their overall health
 - **b.** Patients feel physicians are more able to determine their needs and values than they are
 - **c.** Patients want to avoid disability, be free of pain and discomfort, avoid medication side effects, keep their medical costs low, and postpone death
 - d. Patient-reported outcomes are meaningless
- **3.** The HAQ disability index (HAQ-DI):
 - a. Assesses a patient's overall health status
 - **b.** Evaluates physical function by including items that assess fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities
 - **c.** Is comprised of 10 items organized into 8 categories
 - **d.** All of the above

II.b.

Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care – *T. Pincus, Y. Yazici & M. Bergman*

- 1. The primary goal in development of the MDHAQ was:
 - **a.** Greater reliability than the standard HAQ
 - b. Higher correlations with joint counts than the HAQ
 - c. Greater capacity than the HAQ to distinguish active from control treatment in clinical trials
 - d. Greater ease than the HAQ to review ("eyeball") and score in standard clinical practice
- 2. The MDHAQ includes information not available on the HAQ, MHAQ, or HAQII concerning: a. Employment and work status
 - **b.** History of comorbidities
 - **c.** Complex activities of daily living, such as walking 2 miles or 3 km, and participating in recreation and sports
 - d. Scores for self-efficacy in clinical treatment
- 3. The "constant region" found on all versions of the MDHAQ includes:
 - a. Scores for physical function, pain, and patient global status
 - **b.** Scores for physical function, fatigue and helplessness
 - **c.** Self-report joint count
 - d. The disease activity score (DAS)

II.c.

Why the HAQ-II can be an effective substitute for the HAQ - F. Wolfe

- 1. The HAQ-II is distinguished from the HAQ and MDHAQ by:
 - **a.** Inclusion of a depression scale
 - **b.** Improved scaling properties as a good "ruler"
 - c. More commonly performed activities of daily living
 - d. Helplessness scale
- 2. The HAQ-II and MDHAQ differ from the HAQ by having:
 - a. 10 activities of daily living instead of 25
 - **b.** 8 activities of daily living instead of 20
 - c. 10 activities of daily living instead of 20
 - **d.** 8 activities of daily living instead of 25
- 3. With respect to sensitivity to change in clinical trials, the HAQ-II, MDHAQ, and HAQ are characterized by: a. The HAQ-II is substantially more sensitive
 - **b.** The HAQ is substantially more sensitive
 - c. The MDHAQ is substantially more sensitive
 - d. All 3 performed similarly

II.d.

Measuring functional disability in early rheumatoid arthritis: The validity, reliability and responsiveness of the Recent-Onset Arthritis Disability (ROAD) index -F. Salaffi, A. Stancati, R. Neri, W. Grassi, S. Bombardieri

- 1. The ROAD questionnaire includes 4 scores, all except one below:
 - **a.** Upper extremity function score
 - **b.** Lower extremity function score
 - c. Activities of daily living/work score
 - d. Pain score
- **2.** Which one of these activities is found on the ROAD and not the HAQ (the others are found on both questionnaires)?:
 - **a.** Accept a hand shake
 - **b.** Open jars which have been previously opened
 - c. Reach up and take down a 2 Kg object from above your head
 - d. Walk on flat ground
- 3. ROAD scores are correlated significantly with all these other measures except :
 - a. Pain scores
 - **b.** Joint swelling score
 - **c.** Disease activity score (DAS)
 - d. C-reactive protein

II.e.

The consequences of rheumatoid arthritis: Quality of life measures in the individual patient -

- L. Pollard, E.H. Choy & D.L. Scott
- **1.** The physical health score (PHS) is composed of four subscales on the Short-form 36 (SF-36) including all but which one:
 - a. Physical function
 - **b.** Role-physical
 - **c.** Bodily pain
 - d. Vitality
- 2. A major advantage of the SF-36 compared to the HAQ in studies of rheumatic diseases involves:a. The SF-36 is more sensitive than the HAQ in clinical trials
 - **b.** The SF-36 is correlated at higher levels than the HAQ with the joint count
 - **c.** The SF-36 is used in research concerning many other diseases, allowing possible comparisons to rheumatic diseases
 - d. The SF-36 is more easily completed by patients than the HAQ
- 3. The Nottingham health profile has six subscales, not including one of those listed below:
 - a. Pain
 - **b.** Employment activities
 - c. Sleep
 - **d.** Emotional status

II.f.

The promise of PROMIS: Using item response theory to improve assessment of patient-reported outcomes – *B. Bruce, J. Fries & D. Cella*

- **1.** C.A.T. stands for:
 - a. Challenging Astronomical Technologies
 - **b.** Computerized Adaptive Testing
 - **c.** A small feline
 - d. Computational Advancement of Testing

- **2.** Aims of PROMIS include:
 - a. Helping to set up standardized and universal questionnaire mailing systems for the NIH
 - **b.** Insuring that everyone in the NIH Roadmap keeps their word
 - **c.** Development of large item banks and improved items which are meaningful, precise, and which permit smaller sample sizes in clinical trials while retaining the same statistical power
 - **d.** All of the above

3. IRT:

- a. Stands for the institutional review test.
- **b.** Are measurement models that will help transition conventional health status assessment into an era of item banking and computerized adaptive testing (CAT)
- **c.** Is an acronym for item response theory
- d. Both b and c

III.a.

Quantitative joint assessment in rheumatoid arthritis - T. Sokka & T. Pincus

- **1.** The minimum number of joints in a widely accepted joint count is:
 - **a.** 42
 - **b.** 36
 - **c.** 28
 - **d.** 18
- **2.** Which of the following statements is true concerning joint findings 5 years after baseline associated with traditional treatment for rheumatoid arthritis:
 - a. Tenderness, swelling, and limited motion are all worse 5 years after baseline
 - **b.** Swelling is better, while tenderness and limited motion are worse 5 years after baseline
 - c. Tenderness and swelling are better, while limited motion is worse 5 years after baseline
 - d. Tenderness, swelling, and limited motion are all better 5 years after baseline
- 3. A patient self-report count of painful joints is known as:
 - a. Ritchie index
 - **b.** Lansbury index
 - c. Arthritis impact measurement scales (AIMS)
 - d. Rheumatoid arthritis disease activity index (RADAI)

III.b.

Radiographic progression in rheumatoid arthritis – R. Landewé & D. van der Heijde

- 1. The van der Heijde modification of the Sharp radiographic score adds radiographs of which joints to those of the hands:
 - a. Knees
 - **b.** Feet
 - **c.** Knees and feet
 - **d.** Hips and knees
- 2. The maximum possible total Sharp/van der Heijde radiographic score includes:
 a. 100 units for erosion and 100 units for joint space narrowing= 200 units total
 b. 180 units for erosion and 100 units for joint space narrowing= 280 units total
 c. 200 units for erosion and 100 units for joint space narrowing= 300 units total
 d. 280 units for erosion and 168 units for joint space narrowing= 448 units total
- **3.** ASimplified Erosion and Narrowing Score ("SENS"), designed for standard clinical care differs from more detailed methods by:
 - a. Scoring only certain joints in the hands
 - **b.** Scoring only certain joints in the feet
 - c. Scoring only certain joints in the hands and feet
 - d. Scoring joints as simply abnormal or normal rather than graded scores

III.c.

The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis: A systematic review *J.P. Riedemann, S. Muñoz & A. Kavanaugh*

- 1. The diagnostic properties of anti-CCP2 antibodies in the diagnosis of rheumatoid arthritis include: a. High sensitivity and specificity in all individuals with RA
 - **b.** The sensitivity is low but specificity is high in most patients
 - c. Both sensitivity and specificity are rather low
 - **d.** Sensitivity is high only in individuals with established RA
 - e. A positive result is always indicative of RA
- 2. In a patient with undifferentiated polyarthritis, what is a rational interpretation of a positive anti-CCP2 result?a. It always means that the patient has RA
 - **b.** It is highly likely that the individual either has or will develop RA
 - c. Since the sensitivity in these patients is rather low, it would be best to repeat the test
 - d. Most likely, the patient has psoriatic arthritis
 - e. The meaning of the result depends on the results of a test for rheumatoid factor
- **3.** In patients with established RA, what might be the usefulness of a positive anti-CCP2 antibody? **a.** Immediately discards any overlap with other rheumatic diseases
 - **b.** High titres of the test are associated with higher risk of radiological damage
 - c. The presence of anti-CCP2 antibodies is associated with progressive radiological damage
 - **d.** It is the best predictor of future disability
 - e. It is associated with poor response to conventional DMARD treatment

III.d.

Assessment of pain in rheumatic diseases - T. Sokka

- 1. Pain is most commonly measured in clinical trials in rheumatology according to:
 - a. Melzack Pain Index
 - **b.** Visual Analog Scale
 - c. Short Form 36 (SF36)
 - **d.** Dolorimeter
- 2. The ratio of pain scores to physical function scores in fibromyalgia and RAis characterized by:
 - a. A high ratio is rarely seen in fibromyalgia or RA
 - **b.** A high ratio indicates a higher likelihood of fibromyalgia versus RA
 - c. A low ratio indicates a higher likelihood of fibromyalgia versus RA
 - d. Is not of value in distinguishing fibromyalgia from RA
- **3.** In the US National Health and Nutrition Examination Survey (NHANES1), what proportion of people who had stage 3 or 4 osteoarthritis of the knee did not report any pain:
 - **a.** 20%
 - **b.** 30%
 - **c.** 40%
 - **d.** 50%

III.e.

Rheumatology function tests: Physical measures of functional status to predict mortality in rheumatoid arthritis – *T. Pincus*

- **1.** Apossible advantage of physical measures such as grip strength and walking time compared to patient questionnaires to assess functional status of patients with rheumatoid arthritis is:
 - a. Physical measures are assessed by a health professional and therefore more accurate
 - b. Physical measures do not incorporate as many sociocultural biases as patient questionnaires
 - **c.** Physical measures require less time than patient questionnaires
 - d. Physical measures are included in the ACR Core Data Set

- **2.** The following measures have been found to be significant predictors of mortality over 5-15 years in rheumatoid arthritis:
 - a. Grip strength
 - **b.** Walking time
 - **c.** Button test
 - **d.** All of the above
- **3.** The inter-observer reliability when physical measures such as grip strength and walking time are performed according to a standard protocol is statistically significant and involves correlations at r values of:
 - **a.** 0.35
 - **b.** 0.50
 - **c.** 0.65
 - **d.** 0.80

III.f.

Laboratory monitoring of biological therapies – J.J. Cush & Y. Yazici

- 1. Which one of the following is the most frequent serious adverse event reported with TNF inhibitor use?
 - a. Tuberculosis
 - **b.** Lymphoma
 - c. Congestive heart failure
 - d. Hepatic failure
- **2.** What percentage of rheumatologists surveyed (n=1021) report that they place a PPD before starting a TNF inhibitor?
 - **a.** 21
 - **b.** 39
 - **c.** 59
 - **d.** 77
- **3.** What 3 measures do United States rheumatologists most commonly monitor before starting TNF inhibitors in RA patients?
 - a. CBC, ESR, CRP
 - **b.** PPD, ESR, HAQ
 - c. Physician overall assessment, CBC, ESR
 - d. ESR, DAS score, CBC

IV.a.

The Disease Activity Score and the EULAR response criteria - J. Fransen & P.L.C.M. van Riel

- 1. The disease activity score (DAS) includes all of the following measures except:
 - a. Swollen joint count
 - **b.** Tender joint count
 - **c.** Health assessment questionnaire (HAQ)
 - **d.** Patient assessment of global health
- 2. The disease activity score (DAS) indicating severe disease is generally regarded as:
 - **a.** > 6.2
 - b. > 5.1
 - **c.** > 4.0
 - **d.** > 3.5

3. The disease activity score (DAS) indicating low disease activity is interpreted as:

- **a.** < 1.2
- **b.** < 1.8
- **c.** < 2.6
- **d.** < 3.2

IV.b.

The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): Areview of their usefulness and validity in rheumatoid arthritis – *D. Aletaha & J.S. Smolen*

- 1. The Simplified Disease Activity Index (SDAI) is the numerical sum of:
 - a. Swollen joint count, tender joint count, patient pain assessment, physician global assessment and CRP
 - b. Swollen joint count, tender joint count, patient global assessment, physician global assessment and CRP
 - c. Swollen joint count, tender joint count, patient global assessment, physician global assessment and ESR
 - d. Swollen joint count, tender joint count, health assessment questionnaire (HAQ) and CRP
- 2. Clinical Disease Activity Index (CDAI) differs from the Simplified Disease Activity Index (SDAI) in not including:
 - **a.** Tender joint count
 - **b.** HAQ score
 - c. CRP
 - **d.** All of the above
- **3.** The index which would allow for the highest number of swollen joints in identifying patients who are thought to be in remission is:
 - a. The CDAI
 - **b.** The DAS28
 - c. ACR-N
 - d. The SDAI

IV.c.

The American College of Rheumatology (ACR) Core Data Set and derivative "patient-only" indices to assess rheumatoid arthritis – T. *Pincus*

- 1. The seven measures in the ACR Core Data Set include all of the following except:
 - a. Patient estimate of global status
 - **b.** Patient pain score
 - c. Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)
 - **d.** Grip strength
- 2. Analyses of the relative efficiency of individual ACR Core Data Set measures compared to tender joint count indicated that:
 - a. Patient global had higher relative efficiency
 - **b.** Swollen joint count had higher relative efficiency
 - **c.** ESR had higher relative efficiency
 - **d.** All of the above
- **3.** Acontinuous index of only the three patient measures in the Core Data Set, i.e. physical function, pain, and patient global, compared to the ACR-20 in clinical trials:
 - a. Gives significantly poorer results than the ACR-20 and DAS
 - **b.** Gives similar results to the ACR-20 but poorer than DAS
 - c. Gives similar results to ACR-20 and to DAS
 - d. Gives poorer results than the ACR-20 but similar to DAS

IV.d.

A 3-page standard protocol to evaluate rheumatoid arthritis (SPERA): Efficient capture of essential data for clinical trials and observational studies – *T. Pincus*

- **1.** The five core domains listed in a consensus for long-term observational studies by the outcome measures in rheumatoid arthritis clinical trials (OMERACT) conference include:
 - a. Health status, disease process, joint replacement surgeries, costs, and employment
 - **b.** Health status, disease process, damage, mortality, toxicity/adverse reactions
 - c. Costs, joint replacement, disease process, mortality, psychological distress
 - d. Psychological distress, damage, joint replacement, disease process, toxicity/adverse reactions

- **2.** Aproposed standard protocol to evaluate rheumatoid arthritis (SPERA) includes collection of which of the following information at baseline:
 - **a.** Immunoglobulin levels
 - **b.** Comorbidities
 - **c.** Beck depression inventory
 - **d.** SF-36
- **3.** An advantage of a proposed standard protocol to evaluate rheumatoid arthritis (SPERA) would include: **a.** Identification of which patients require assessment using anti-CCP
 - **b.** Identification of patients who are candidates for joint replacement surgery
 - c. Recognition of extraarticular disease
 - d. Recognition of which patients will require biologic therapies

V.a.

Assessment of systemic lupus erythematosus – G. Lam & M. Petri

- 1. Assessment of SLE renal disease activity and damage is best performed by:
 - **a.** Comprehensive urinalysis
 - **b.** 24 hour urine collection for protein
 - **c.** Renal biopsy
 - d. Urine protein-to-creatinine ratio
- 2. In SLE patients, overall health status most strongly correlates with:
 - a. Psychosocial factors and fibromyalgia
 - b. Disease activity
 - **c.** Organ damage
 - **d.** Age
- 3. Limitations to the current ACR Criteria for the classification of SLE include:
 - a. Over-representation of cutaneous manifestations of lupus
 - **b.** Lack of cross-cultural and ethnic validation
 - **c.** Decreased sensitivity for early disease
 - **d.** All of the above

V.b.

Assessment of ankylosing spondylitis - J. Zochling & J. Braun

- 1. The ASAS core set for clinical record keeping does not include:
 - a. Spinal pain
 - **b.** Spinal mobility
 - c. Acute phase reactants
 - **d.** Physical function
 - e. Spinal x-ray
- 2. In clinical practice, the most useful single measure of patient status is thought to be:
 - **a.** Spinal pain
 - **b.** Duration of morning stiffness
 - **c.** Patient global assessment
 - d. ESR
 - e. Radiological change in the spine
- **3.** Elevation of acute phase reactants (ESR, CRP) is a sensitive indicator of: **a.** Spinal inflammation
 - **b.** Peripheral joint inflammation
 - **c.** Poor prognosis
 - **d.** Disease progression
 - e. Spinal stiffness

V.c.

The assessment of disease activity and outcomes in psoriatic arthritis - A. Kavanaugh & S. Cassell

- 1. Assessing clinical outcomes in psoriatic arthritis is challenging because:
 - a. No good treatments are available for psoriatic arthritis
 - **b.** All patients with psoriatic arthritis have similar disease manifestations
 - c. No outcome measures have been shown to be reliable in psoriatic arthritis
 - d. It is a multi-faceted disease
- **2.** Components of the Disease Activity Score (DAS) used in psoriatic arthritis include all of the following except:
 - **a.** Swollen joint count
 - b. Psoriasis Area and Severity Index (PASI)
 - **c.** Patient global assessment of arthritis
 - d. Inflammatory markers (CRP or ESR)
- 3. Important features of disease activity to assess in psoriatic arthritis can include:
 - **a.** Skin disease
 - b. Peripheral arthritis
 - **c.** Enthesopathy
 - **d.** All of the above

V.d.

The WOMAC Knee and Hip OAIndices: Development, validation, globalization and influence on the development of the AUSCAN Hand OA Indices – N. Bellamy

- **1.** The Western Ontario and McMaster (WOMAC) Osteoarthritis Index questionnaire was developed initially from:
 - a. An OMERACT consensus conference
 - **b.** A thesis of an individual
 - c. The Osteoarthritis Research Society (OARS)
 - d. The ARAMIS national database
- 2. In the original version of the WOMAC scales for all of the following performed well, except for:
 - **a.** Pain
 - **b.** Stiffness
 - c. Physical
 - d. Social
- 3. The following formats have been used effectively for WOMAC scoring:
 - a. 5-point Likert scale
 - **b.** Visual analog scales
 - c. 5-point pictorial scale
 - d. 11-point numerical rating scale

V.e.

The Fibromyalgia Impact Questionnaire (FIQ): A review of its development, current version, operating characteristics and uses – *R. Bennett*

- **1.** How many questions are incorporated into the FIQ?
 - **a.** 10
 - **b.** 15
 - **c.** 20
 - **d.** 30

- 2. Some previous versions of the FIQ have omitted questions 3 and 4 and employed a maximum possible FIQ score 80. What is the current recommendation regarding the recording of the total FIQ score in such a case?a. Adjust the final score by a multiplication factor of 1.25
 - **b.** Adjust the final score by a division factor of 1.25
 - **c.** Add 20 to the score
 - d. Make no adjustment
- 3. Which of the following statements are correct:
 - a. There is a significant correlation between higher FIQ scores and work related disability
 - b. There is no significant correlation between higher FIQ scores and psychological distress
 - c. Patients with chronic pain problems, other than fibromyalgia, seldom report a FIQ score >50
 - d. The FIQ is a subset of the health assessment questionnaire (HAQ)

VI.a.

The Arthritis, Rheumatism and Aging Medical Information System (ARAMIS): Still young at 30 years – *B. Bruce & J.F. Fries*

- 1. ARAMIS was one of the first:
 - a. Computerized data banks
 - b. National chronic disease data bank systems
 - c. Longitudinal studies to be done
 - d. All of the above
 - $\boldsymbol{e}\boldsymbol{.}$ a and b only
- **2.** ARAMIS patient data come from:
 - a. A random sampling of about 14,000 rheumatic disease patients
 - b. Consecutively enrolled rheumatic disease patients
 - c. Patients in the United States only
 - **d.** All of the above
- 3. ARAMIS has made significant contributions to a paradigm shift in:
 - **a.** Use of scannable HAQs to streamline data collection
 - b. Patient enrollment methods
 - **c.** Measurement of patient outcomes
 - **d.** Methods of mortality assessment

VI.b.

Abrief introduction to the National Databank for Rheumatic Diseases - F. Wolfe

- 1. The National Databank of Rheumatic Diseases founded in 1998 currently includes approximately how many patients?
 - **a.** 8,000
 - **b.** 14,000
 - **c.** 28,000
 - **d.** 48,000
- **2.** The National Databank (NDB) estimates for prevalence of diarrhea in 6,011 users of Leflunomide was approximately:
 - **a.** 7%
 - **b.** 12%
 - **c.** 17%
 - **d.** 27%
- 3. Features of the National Databank practices include:
 - a. Routine validation of the work of assessors and interviewers
 - **b.** Routine contact with patients who do not return questionnaires or withdraw from study
 - c. Annual searches of the national death index for patients who have not returned questionnaires
 - **d.** All of the above

VI.c.

The CORRONA Database - J. Kremer

- **1.** All of the following favor the adoption of an Internet based database:
 - a. Almost universal electronic centered technology in rheumatologists' offices
 - **b.** Increased need to monitor outcomes of newly approved agents
 - **c.** Billing documentation
 - d. The need to document quality
 - e. All of the above
- 2. The CORRONAdatabase is:
 - a. Run by industry
 - b. Run by a group of independent rheumatologist/clinical investigators
 - c. Subject to industry veto over its chosen research activities
 - **d.** Now the largest independent database in the world in rheumatology which collects data at the time of a clinical encounter from both rheumatologists and patients
 - e. b and d are correct
- 3. The following can be calculated from the CORRONA database:
 - a. SLEDAI, BILAG
 - b. Modified Sharp scores, SF-36
 - **c.** ACR 20,50 and 70, DAS 28
 - **d.** Folate index
 - e. Psoriasis skin score

VI.d.

An Early Rheumatoid Arthritis Treatment Evaluation Registry (ERATER) in the United States –

T. Sokka & T. Pincus

- 1. One relatively unusual feature of an Early Rheumatoid Arthritis Treatment Evaluation Registry in US is: a. Inclusion of joint counts
 - b. Inclusion of all patients with early RA regardless of therapies
 - c. SF-36 questionnaire
 - **d.** All of the above
- **2.** In the ERATER US Early Arthritis Database approximately what proportion of patients took methotrexate as their first DMARD?
 - **a.** 20%
 - **b.** 40%
 - **c.** 60%
 - **d.** 80%
- **3.** In the ERATER database what proportion of patients met the criterion of eligibility for the Early Rheumatoid Arthritis (ERA) clinical trial of etanercept versus methotrexate?
 - **a.** 20%
 - **b.** 30%
 - **c.** 40%
 - **d.** 50%
 - **e.** 60%

VI.e.

Adatabase in private practice: The Brooklyn Outcomes of Arthritis Rheumatology Database (BOARD) - Y. Yazici

- 1. The Brooklyn Outcomes of Arthritis in Rheumatology Database is designed to include:
 - a. Patients with rheumatoid arthritis
 - b. Patients with inflammatory rheumatic diseases
 - c. Patients with rheumatoid arthritis, osteoarthritis, and fibromyalgia
 - d. All patients seen in a private rheumatology practice setting

- 2. Analysis of pain scores in the BOARD database indicated that the highest levels were seen in: a. Hispanic patients
 - **a.** Hispanic patients **b** African American pat
 - **b.** African-American patients**c.** Caucasian patients
 - **d.** Asian patients
 - **a.** Asian patients
- 3. One unique feature in monitoring patients on the questionnaire for the BOARD includes:
 - a. Beck depression inventory
 - **b.** SF-36 questionnaire
 - c. Physician's note with physician's global on the same page as the patient questionnaire
 - **d.** Self-report joint count

VI.f.

ANorwegian DMARD register: The prescription of DMARDs and biological agents to patients with inflammatory rheumatic diseases -T.K. Kvien, M.S. Heiberg, E. Lie, C. Kaufmann, K. Mikkelsen, B.-Y. Nordvåg & E. $R\phi devand$

- **1.** Among 4,683 patients entered into the Norway DMARD Registry (NOR-DMARD), approximately what percent had rheumatoid arthritis?
 - **a.** 48%
 - **b.** 58%
 - **c.** 68%
 - **d.** 78%
- 2. Approximately what proportion of the NOR-DMARD registry had unspecified arthritis?
 - **a.** 5%
 - **b.** 10%
 - **c.** 15%
 - **d.** 25%

3. The most frequently prescribed disease-modifying anti-rheumatic drug in NOR-DMARD was:

- a. Methotrexate
- **b.** Etanercept
- c. Infliximab
- **d.** Anakinra
- e. Adalimumab

VI.g.

Rheumatoid arthritis registries in Sweden – R.F. van Vollenhoven & J. Askling

- 1. Which is the main difference between a randomized trial and an observational study?
 - a. Randomized trials deal with effects, observational studies with side-effects
 - b. Randomized trials have guaranteed validity, while observational studies do not
 - **c.** Treatment is allocated by chance in randomized trials and by the treating physicians'choice in observational studies
 - d. Observational studies deal with selected populations, which limit their generalizability
- 2. The Swedish registry ARTIS is:
 - a. An inception cohort
 - **b.** Asystem for voluntary adverse-event reporting
 - c. Aregistry for patients who take biologic agents
 - d. Along-term clinical trial
- 3. The Swedish biologics registries have provided data showing:
 - a. An increased risk of solid tumors with biologic treatments
 - **b.** Superiority of biologics over traditional DMARDs
 - c. Atemporal trend to treating patients with lesser active disease with biologicals
 - d. Atemporal trend to treating patients with lesser functional impairment with biologicals

VI.h.

Rheumatoid arthritis databases in Finland - T. Sokka

- 1. The primary outcome in the FIN-RACo clinical trial in rheumatoid arthritis was:
 - **a.** ACR-20
 - **b.** ACR-50
 - **c.** DAS less than 2.8
 - d. Remission including no tender or swollen joints, pain, morning stiffness, or elevated sedimentation rate
- **2.** The prevalence of remission in the three groups receiving combination therapy, monotherapy within four months of presentation, and monotherapy after four months of presentation was:
 - a. 37%, 35%, and 11% in the three groups respectively
 - **b.** 24%, 15%, and 11% in the three groups respectively
 - c. 22%, 6%, and 2% in the three groups respectively
 - d. 34%, 18%, 8% in the three groups respectively
- **3.** In mailed surveys to the general population, which of the following predicted a higher likelihood of mortality over 2 years?
 - a. High levels of functional disability according to the HAQ
 - **b.** Morning stiffness
 - c. Non-response to the questionnaire
 - $\boldsymbol{d.}$ a and \boldsymbol{c}

VI.i.

DANBIO: Anationwide registry of biological therapies in Denmark - M.L. Hetland

- 1. The Danish DANBIO registry is characterized by:
 - **a.** Being nationwide
 - b. Includes all rheumatologic diagnoses
 - c. The information technology IT-platform is based on open-source software
 - d. Monitoring patients across different biological therapies
 - e. All of the above
- 2. Data from the DANBIO registry have indicated that:
 - a. Earlier use of biologic agents in patients with milder disease since these agents were first marketed
 - **b.** Registration of adverse events on a routine-based set-up results in a twenty-fold increase in collection of non-serious adverse events
 - c. Biological therapies result in an increased risk of infection
 - **d.** 92% of patients had been taking methotrexate prior to initiation of a biological drug
 - **e.** All of the above
- 3. The high level of participation in the DANBIO registry may be explained in large part by:
 - **a.** It is mandatory to report to the registry
 - **b.** Systematic return of efficacy data to the rheumatologist
 - c. Danish rheumatologists have a long tradition of routine-based data collection
 - d. Rheumatologists are reimbursed for participation